Evidence map›Paper›PMID 33128769›Full record

Trial reportBritish journal of haematology2021

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.

Frits van Rhee, Jean-François Rossi, David Simpson, Alexander Fosså, Angela Dispenzieri, John Kuruvilla, Yeow Tee Goh, Seok-Goo Cho, Marcelo Capra, Ting Liu and 3 more

Abstract readClinical Trial, Phase IILetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How we manage idiopathic multicentric Castleman disease.Clinical advances in hematology & oncology : H&O · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Frits van RheeMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0001-9959-1282
Jean-François RossiInstitut Sainte Catherine, Avignon, France.
David SimpsonBeiGene, San Mateo, CA, USA.
Alexander FossåOslo University Hospital, Oslo, Norway.
Angela DispenzieriMayo Clinic, Rochester, MN, USA.
John KuruvillaPrincess Margaret Cancer Centre, Toronto, Canada.
Yeow Tee GohSingapore General Hospital, Singapore, Singapore.
Seok-Goo ChoSeoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0002-5429-4839
Marcelo CapraInstituto do Cancer, Hospital Mãe de Deus, Porto Alegre, Brazil.
Ting LiuWest China Hospital of Sichuan University, Chengdu, China.
Corey CasperInfectious Disease Research Institute, Seattle, WA, USA.
James CavetChristie Hospital & University of Manchester, Manchester, UK.
Raymond S WongSir YK Pao Centre for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.

Funding

EUSA PHARMAJanssen Research & Development
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsCastleman DiseaseHumansPlacebo EffectProportional Hazards ModelsTreatment OutcomeAntibodies, MonoclonalAntineoplastic Agentssiltuximabmulticentric Castleman diseasesiltuximab

Identifiers

PMID33128769
PMCPMC7820993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.